MX2020011959A - Compuestos de heteroarilo y usos de los mismos. - Google Patents
Compuestos de heteroarilo y usos de los mismos.Info
- Publication number
- MX2020011959A MX2020011959A MX2020011959A MX2020011959A MX2020011959A MX 2020011959 A MX2020011959 A MX 2020011959A MX 2020011959 A MX2020011959 A MX 2020011959A MX 2020011959 A MX2020011959 A MX 2020011959A MX 2020011959 A MX2020011959 A MX 2020011959A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- heteroaryl compounds
- compositions
- solvates
- hydrates
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/0429—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K51/0431—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
- C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
- C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
- C09K19/3483—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a non-aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
- C09K19/3491—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having sulfur as hetero atom
- C09K19/3497—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having sulfur as hetero atom the heterocyclic ring containing sulfur and nitrogen atoms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En el presente documento se describen compuestos de fórmula (I), y sales farmacéuticamente aceptables, solvatos, hidratos, derivados marcados isotópicamente y derivados radiomarcados de los mismos, y composiciones farmacéuticas de los mismos. También se proporcionan métodos y kits que implican los compuestos o las composiciones de la invención para detectar y obtener imágenes de agregados de Tau en el cerebro para la detección de enfermedad de Alzheimer (EA) en un sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018086144 | 2018-05-09 | ||
PCT/CN2019/086201 WO2019214681A1 (en) | 2018-05-09 | 2019-05-09 | Heteroaryl compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020011959A true MX2020011959A (es) | 2021-02-17 |
Family
ID=68467203
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011959A MX2020011959A (es) | 2018-05-09 | 2019-05-09 | Compuestos de heteroarilo y usos de los mismos. |
Country Status (14)
Country | Link |
---|---|
US (3) | US20210253569A1 (es) |
EP (1) | EP3790883A4 (es) |
JP (1) | JP7293343B2 (es) |
KR (1) | KR102572014B1 (es) |
CN (1) | CN112384517B (es) |
AU (1) | AU2019265346B2 (es) |
BR (1) | BR112020022741A2 (es) |
CA (1) | CA3099318C (es) |
IL (1) | IL278579B1 (es) |
MX (1) | MX2020011959A (es) |
SG (1) | SG11202010946YA (es) |
TW (1) | TW201946624A (es) |
WO (1) | WO2019214681A1 (es) |
ZA (1) | ZA202007547B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102053484B1 (ko) | 2012-12-21 | 2019-12-06 | 국립연구개발법인 양자과학기술연구개발기구 | 뇌 안에 축적된 타우 단백질을 이미징하기 위한 신규한 화합물 |
KR20210097096A (ko) * | 2018-11-29 | 2021-08-06 | 호도가야 가가쿠 고교 가부시키가이샤 | 아자벤조옥사졸 고리 구조를 갖는 화합물 및 유기 일렉트로루미네선스 소자 |
EP4058065A4 (en) * | 2019-11-13 | 2023-05-03 | Aprinoia Therapeutics Limited | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND THEIR USES |
EP4219459A4 (en) * | 2020-09-25 | 2024-03-27 | Jumbo Drug Bank Co., Ltd. | 1H-PYRROLO[2,3-C PYRIDINE COMPOUNDS AND THEIR USE |
CA3218573A1 (en) | 2021-05-14 | 2022-11-17 | Ming-Kuei Jang | Compounds for degrading alpha-synuclein aggregates and uses thereof |
TWI782769B (zh) * | 2021-10-28 | 2022-11-01 | 行政院原子能委員會核能研究所 | 一種新穎神經纖維糾結微管相關蛋白質Tau造影化合物、其製備方法及用途 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61145285A (ja) * | 1984-12-20 | 1986-07-02 | Mitsui Toatsu Chem Inc | ベンゾチアゾ−ル環を有するアゾ系液晶表示用二色性色素 |
JPH0218456A (ja) * | 1988-07-06 | 1990-01-22 | Mitsui Toatsu Chem Inc | アントラキノン系色素の製造方法 |
JP2854908B2 (ja) * | 1990-01-23 | 1999-02-10 | 三井化学株式会社 | イミド化合物の製造方法 |
JP2005514382A (ja) * | 2001-11-30 | 2005-05-19 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−5モジュレーター |
ES2379169T3 (es) * | 2003-05-19 | 2012-04-23 | Irm Llc | Composiciones y compuestos inmunosupresores |
WO2007034277A1 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists |
WO2007034282A2 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists |
EP1964840A1 (en) * | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]pyridines and their use as pharmaceuticals |
US8420052B2 (en) * | 2008-07-24 | 2013-04-16 | Siemens Medical Solutions Usa, Inc. | Imaging agents useful for identifying AD pathology |
CA2737028C (en) * | 2008-09-23 | 2017-06-27 | Wista Laboratories Ltd. | Ligands for aggregated tau molecules |
US8691187B2 (en) * | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
WO2010111303A2 (en) * | 2009-03-23 | 2010-09-30 | Siemens Medical Solutions Usa, Inc. | Imaging agents for detecting neurological disorders |
UA108363C2 (uk) * | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
WO2011045415A2 (en) * | 2009-10-15 | 2011-04-21 | Guerbet | New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
KR101116234B1 (ko) * | 2009-10-29 | 2014-03-06 | (주)퓨쳐켐 | (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 |
KR102053484B1 (ko) * | 2012-12-21 | 2019-12-06 | 국립연구개발법인 양자과학기술연구개발기구 | 뇌 안에 축적된 타우 단백질을 이미징하기 위한 신규한 화합물 |
WO2015188368A1 (en) * | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles |
WO2016132998A1 (ja) * | 2015-02-19 | 2016-08-25 | Jnc株式会社 | ベンゾチオフェンを有する液晶性化合物、液晶組成物および液晶表示素子 |
WO2017108282A1 (en) * | 2015-12-22 | 2017-06-29 | Kancera Ab | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity |
US10300155B2 (en) * | 2015-12-31 | 2019-05-28 | Washington University | Alpha-synuclein ligands |
US10059878B2 (en) * | 2016-02-17 | 2018-08-28 | Jnc Corporation | Liquid crystal composition and liquid crystal display device |
JP6696312B2 (ja) * | 2016-06-15 | 2020-05-20 | Jnc株式会社 | 液晶組成物および液晶表示素子 |
WO2018055316A1 (fr) * | 2016-09-26 | 2018-03-29 | Centre National De La Recherche Scientifique | Composes pour leur utilisation en imagerie et notamment pour le diagnostic de maladies neuro-degeneratives |
-
2019
- 2019-05-09 JP JP2021512993A patent/JP7293343B2/ja active Active
- 2019-05-09 BR BR112020022741-2A patent/BR112020022741A2/pt unknown
- 2019-05-09 TW TW108116060A patent/TW201946624A/zh unknown
- 2019-05-09 KR KR1020207035348A patent/KR102572014B1/ko active IP Right Grant
- 2019-05-09 CA CA3099318A patent/CA3099318C/en active Active
- 2019-05-09 MX MX2020011959A patent/MX2020011959A/es unknown
- 2019-05-09 IL IL278579A patent/IL278579B1/en unknown
- 2019-05-09 SG SG11202010946YA patent/SG11202010946YA/en unknown
- 2019-05-09 AU AU2019265346A patent/AU2019265346B2/en active Active
- 2019-05-09 CN CN201980045369.5A patent/CN112384517B/zh active Active
- 2019-05-09 WO PCT/CN2019/086201 patent/WO2019214681A1/en active Search and Examination
- 2019-05-09 US US17/054,015 patent/US20210253569A1/en active Pending
- 2019-05-09 EP EP19800625.6A patent/EP3790883A4/en active Pending
-
2020
- 2020-12-03 ZA ZA2020/07547A patent/ZA202007547B/en unknown
-
2021
- 2021-09-16 US US17/477,411 patent/US20230047178A1/en not_active Abandoned
-
2023
- 2023-08-02 US US18/229,588 patent/US20230374006A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202010946YA (en) | 2020-12-30 |
KR20210008049A (ko) | 2021-01-20 |
BR112020022741A2 (pt) | 2021-02-02 |
AU2019265346B2 (en) | 2022-06-16 |
EP3790883A4 (en) | 2022-08-24 |
EP3790883A1 (en) | 2021-03-17 |
US20230047178A1 (en) | 2023-02-16 |
IL278579B1 (en) | 2024-05-01 |
CA3099318A1 (en) | 2019-11-14 |
AU2019265346A1 (en) | 2021-01-07 |
ZA202007547B (en) | 2022-07-27 |
CN112384517B (zh) | 2023-07-14 |
KR102572014B1 (ko) | 2023-08-29 |
TW201946624A (zh) | 2019-12-16 |
CA3099318C (en) | 2024-02-13 |
JP7293343B2 (ja) | 2023-06-19 |
WO2019214681A1 (en) | 2019-11-14 |
CN112384517A (zh) | 2021-02-19 |
IL278579A (en) | 2020-12-31 |
US20210253569A1 (en) | 2021-08-19 |
JP2021523231A (ja) | 2021-09-02 |
US20230374006A1 (en) | 2023-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020011959A (es) | Compuestos de heteroarilo y usos de los mismos. | |
CY1124257T1 (el) | N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA | |
CY1124652T1 (el) | Παραγωγα 1η-ινδαζολο-3-καρβοξαμιδιου και σχετικες ενωσεις ως αναστολεις παραγοντα d για τη θεραπεια νοσων που χαρακτηριζονται απο μη φυσιολογικη δραστηριοτητα συστηματος συμπληρωματος, οπως π.χ. ανοσολογικες διαταραχες | |
CY1123069T1 (el) | Νεα (ετερο)αρυλ-υποκατεστημενα-πιπεριδινυλ παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα | |
UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
WO2020097400A8 (en) | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof | |
EA201892007A1 (ru) | 3-дезоксипроизводное и фармацевтические композиции на его основе | |
NO20081554L (no) | Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav | |
PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
GT200400174A (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5 ht4 | |
TW200640900A (en) | 1-(2h)-isoquinolone derivative | |
NO20080186L (no) | Heterosykliske aspartylproteaseinhibitorer, fremstilling og anvendelse derav | |
CR20140368A (es) | Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036) | |
HRP20070505B1 (hr) | Spiro-oksindol spojevi i njihove upotrebe kao terapijska sredstva | |
CY1114892T1 (el) | Φαρμακευτικη συνθεση ενος ισχυρου αναστολεα του hcv για απο του στοματος χορηγηση | |
CR11333A (es) | cis-IMIDAZOLINAS QUIRALES | |
MX2020010847A (es) | Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes. | |
NO20083598L (no) | Karbosykliske og heterosykliske arylsulfoner som inhibitorer av gamma-sekretase | |
WO2007064553A3 (en) | Thiazole derivatives as cxcr3 receptor modulators | |
TW200800946A (en) | Substituted piperazines as metabotropic glutamate receptor antagonists | |
MY169274A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
CY1124643T1 (el) | Νεα ενωση και φαρμακευτικα αποδεκτο αλας αυτης | |
MX2019014368A (es) | Agentes de imagenologia nuevos para tomografia de emision de positrones (pet) sustituidos con deuterio y su aplicacion farmacologica. | |
ZA202108104B (en) | Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases | |
MX2022000854A (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. |